Learn More About Our Gastric/Esophageal Trials

• 1 PCYC-1128-CA Show More

  PCYC-1128-CA – A Phase1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (Bladder, Colon,Gastric,Renal)

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Advanced GI Cancer (Gastric and Colon).

  2. WHO IS ELIGIBLE?
  Patients who have received prior chemothreapy .

  3. HOW WILL I BE TREATED?
  Patients will receive Ibrutinib with other chemotherapy or biologic therapy

  For Physicians: More information about this specific trial at clinicaltrials.gov

• 2 S0820 Show More

  S0820 – Phase III A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer.

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Colorectal cancers or high-risk adenomas (polyps).

  2. WHO IS ELIGIBLE?
  Patients with Stage 0, I, II, or III disease that is removed who desire prevention.

  3. HOW WILL I BE TREATED?
  This study looks at using two drugs for precention — Sulindac, non-steroidal anti-inflammatory, and eflornithine is a drug that has been shown in a preclinical data to have a role in cancer prevention.

  For Physicians: More information about this specific trial at clinicaltrials.gov

• 3 CX-839-008 Show More

  CX-839-008 – A Phase III, Randomized,Placebo Controlled Study Of ATEZOLIZUMAB(ANTI-PD-L1 ANTIBODY) As Monotherapy And In Combination With Platinum Chemotherapy In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma.

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Renal Cell Cancer.

  2. WHO IS ELIGIBLE?
  Patients with disease progression after first-line therapy.

  3. HOW WILL I BE TREATED?
  Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated with Cabozantinib (a small molecule tyrosine kinase inhibitor).

  For Physicians: More information about this specific trial at clinicaltrials.gov